United Therapeutics Corporation Increase (Decrease) in Other Operating Liabilities
United Therapeutics Corporation (UTHR) reported Increase (Decrease) in Other Operating Liabilities of -$315.46 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2015-02-24
- United Therapeutics Corporation increase (decrease) in other operating liabilities for the quarter ending 2014-12-31 was -$46.48M.
- United Therapeutics Corporation increase (decrease) in other operating liabilities for the quarter ending 2014-09-30 was -$66.71M.
- United Therapeutics Corporation increase (decrease) in other operating liabilities for the quarter ending 2014-06-30 was -$151.38M.
- United Therapeutics Corporation increase (decrease) in other operating liabilities for the quarter ending 2014-03-31 was -$50.89M.
- United Therapeutics Corporation increase (decrease) in other operating liabilities for fiscal 2014 was -$315.46M.
- United Therapeutics Corporation increase (decrease) in other operating liabilities for fiscal 2013 was -$196.64M.
- United Therapeutics Corporation increase (decrease) in other operating liabilities for fiscal 2012 was -$145.76M.
- United Therapeutics Corporation increase (decrease) in other operating liabilities for fiscal 2011 was -$93.56M.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2014-12-31 | -$46.48M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | -$113.19M derived: sum of 2 quarters · filed 2015-02-24 | -$264.57M derived: sum of 3 quarters · filed 2015-02-24 | -$315.46M 10-K · filed 2015-02-24 |
| 2014-09-30 | -$66.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | -$218.09M derived: sum of 2 quarters · filed 2014-10-28 | -$268.98M 10-Q · filed 2014-10-28 | -$311.75M derived: sum of 4 quarters · filed 2015-02-24 |
| 2014-06-30 | -$151.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | -$202.27M 10-Q · filed 2014-07-29 | -$245.04M derived: sum of 3 quarters · filed 2015-02-24 | -$292.27M derived: sum of 4 quarters · filed 2015-02-24 |
| 2014-03-31 | -$50.89M 10-Q · filed 2014-04-29 | -$93.67M derived: sum of 2 quarters · filed 2015-02-24 | -$140.90M derived: sum of 3 quarters · filed 2015-02-24 | -$196.05M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-12-31 | -$42.77M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | -$90.00M derived: sum of 2 quarters · filed 2015-02-24 | -$145.16M derived: sum of 3 quarters · filed 2015-02-24 | -$196.64M 10-K · filed 2015-02-24 |
| 2013-09-30 | -$47.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | -$102.38M derived: sum of 2 quarters · filed 2014-10-28 | -$153.87M 10-Q · filed 2014-10-28 | -$190.31M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | -$55.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | -$106.64M 10-Q · filed 2014-07-29 | -$143.09M derived: sum of 3 quarters · filed 2015-02-24 | -$180.39M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | -$51.48M 10-Q · filed 2014-04-29 | -$87.93M derived: sum of 2 quarters · filed 2015-02-24 | -$125.23M derived: sum of 3 quarters · filed 2015-02-24 | -$164.47M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | -$36.45M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | -$73.75M derived: sum of 2 quarters · filed 2015-02-24 | -$112.98M derived: sum of 3 quarters · filed 2015-02-24 | -$145.76M 10-K · filed 2015-02-24 |
| 2012-09-30 | -$37.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | -$76.54M derived: sum of 2 quarters · filed 2013-10-29 | -$109.31M 10-Q · filed 2013-10-29 | -$184.89M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | -$39.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | -$72.01M 10-Q · filed 2013-07-25 | -$147.58M derived: sum of 3 quarters · filed 2014-02-25 | -$123.81M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | -$32.77M 10-Q · filed 2013-04-25 | -$108.35M derived: sum of 2 quarters · filed 2014-02-25 | -$84.58M derived: sum of 3 quarters · filed 2014-02-25 | -$107.66M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | -$75.58M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$51.80M derived: sum of 2 quarters · filed 2014-02-25 | -$74.89M derived: sum of 3 quarters · filed 2014-02-25 | -$93.56M 10-K · filed 2014-02-25 |
| 2011-09-30 | $23.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $687.00K derived: sum of 2 quarters · filed 2012-11-01 | -$17.98M 10-Q · filed 2012-11-01 | -$61.30M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | -$23.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | -$41.76M 10-Q · filed 2012-07-26 | -$85.07M derived: sum of 3 quarters · filed 2013-02-26 | -$89.80M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | -$18.67M 10-Q · filed 2012-04-26 | -$61.99M derived: sum of 2 quarters · filed 2013-02-26 | -$66.72M derived: sum of 3 quarters · filed 2013-02-26 | -$73.69M derived: sum of 4 quarters · filed 2013-02-26 |
| 2010-12-31 | -$43.31M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$48.05M derived: sum of 2 quarters · filed 2013-02-26 | -$55.02M derived: sum of 3 quarters · filed 2013-02-26 | -$59.68M 10-K · filed 2013-02-26 |
| 2010-09-30 | -$4.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | -$11.71M derived: sum of 2 quarters · filed 2011-10-27 | -$16.36M 10-Q · filed 2011-10-27 | -$32.59M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-06-30 | -$6.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | -$11.63M 10-Q · filed 2011-07-28 | -$27.86M derived: sum of 3 quarters · filed 2012-02-28 | -$38.44M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-03-31 | -$4.66M 10-Q · filed 2011-04-28 | -$20.89M derived: sum of 2 quarters · filed 2012-02-28 | -$31.47M derived: sum of 3 quarters · filed 2012-02-28 | |
| 2009-12-31 | -$16.23M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | -$26.81M derived: sum of 2 quarters · filed 2012-02-28 | -$29.06M 10-K · filed 2012-02-28 | |
| 2009-09-30 | -$10.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | -$12.83M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | -$2.25M 10-Q · filed 2010-07-28 | |||
| 2008-12-31 | $22.42M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |